CClinicalTrials.gg
RecruitingNCT06857344AAS-GEUpdated Aug 15, 2025

Reinforcement Learned Automatic Anesthesia System During Painless Gastrointestinal Endoscopy

An interventional study of AI Controlled General Anesthesia and General Anesthesia (GA) in Anesthesia Induction, sponsored by Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd.. Recruiting at 5 sites in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-15.

Sponsored by Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started May 2025; still recruiting 1 year 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
164
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this clinical trial is to compare the performance difference between trained model and clinical professionals in anesthesia control during gastrointestinal endoscopy. The participants would include adults aged between 18-65 years old with ASA scores I-II. The main questions it aims to answer are:

  • Can AI model successfully and safely perform anesthesia during gastrointestinal endoscopy?
  • Researchers hypothesis that anesthesia performed by professionals is not inferior to those performed by AI model.

The researchers will compare the results of the AI group with the traditional group to see if both groups have similar success rates in performing anesthesia.

Participants will fast for 8 hours before the procedure, and drinking water will be prohibited for 2 hours after taking the intestinal purgatives.

02

Conditions studied

  • Anesthesia Induction
03

In context

Lead sponsor

Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd. is the lead sponsor of 6 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • American Society of Anesthesiologists (ASA) physical status class I-II
  • Expected operation duration less than 1 hour

Exclusion criteria

Exclusion Criteria:

  • History of cardiac, hepatic, renal, or metabolic disorders (e.g., diabetes, hypertension, sleep apnea)
  • Known allergy to opioids or ciprofloxacin components
  • Cachexia
  • Hypothermia; history of narcotic abuse; chronic alcoholism; obesity (BMI >30); patients with apnea
  • Current pregnancy or lactation
  • History of substance abuse or alcohol dependence
  • Participation in any other drug clinical trial within the past 3 months
  • Obesity (BMI >30 kg/m²)
  • Procedure termination due to gastric retention or inadequate bowel preparation
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
164 participants (estimated)

Study arms

  • Experimental
    Test group

    In the test group, participants will receive anesthesia via an AI model.

    Procedure: AI Controlled General Anesthesia

  • Active comparator
    Control group

    In the control group, anesthesia will be induce by experienced anesthesiologists

    Procedure: General Anesthesia (GA)

Interventions

  • ProcedureAI Controlled General Anesthesia

    During gastrointestinal endoscopy, anesthesia will be induced using ciprofol, and controlled by an AI model.

  • ProcedureGeneral Anesthesia (GA)

    Anesthesia will be induced using ciprofol, and controlled by experienced anesthesiologists.

06

What researchers measure

Primary outcomes

  1. Incidence of hypoxemia

    Hypoxemia is defined as blood oxygen saturation below 92% at any time.

    Time frame: During procedure

Secondary outcomes

  1. Area under curve of hypoxemia

    The area where SpO2 is below 92%.

    Time frame: During procedure

  2. Lowest value of blood oxygen saturation

    Time frame: During procedure

  3. Induction and maintenance doses of anesthesia

    Doses are recorded in mg/kg/h. The induction period is defined as the interval from the start of anesthesia to the first BIS value below 60. The maintenance period is defined as the interval from the first BIS value below 60 to the end of the drug infusion.

    Time frame: During procedure

  4. Induction time

    The time interval from the start of drug administration to the first BIS ≤ 1.

    Time frame: During procedure

  5. Complete recovery time

    Time interval from cessation of anesthetic agents to BIS \> 80.

    Time frame: During procedure

  6. Incidence of hypotension

    systolic blood pressure \< 90 mmHg or a 30% decrease from baseline lasting longer than 2 minutes

    Time frame: During procedure

  7. Counts of body movement

    Time frame: During procedure

  8. Dose of norepinephrine

    Time frame: During procedure

  9. Duration of colonoscopy

    Time frame: During procedure

  10. Ciprofol related adverse reactions

    Included sinus bradycardia, dizziness

    Time frame: During procedure

07

Study locations

5 of 5 sites recruiting
  • Anxi County Hospital
    Anxi, Fujian, China
    Recruiting
  • Jinjiang Municipal Hospital, Shanghai Sixth People's Hospital Fujian Campus
    Jinjiang, Fujian, China
    Recruiting
  • Xinzheng Public People's Hospital
    Xinzheng, Henan, China
    Recruiting
  • Henan Provincial People's Hospital
    Zhengzhou, Henan, China
    Recruiting
  • Zhengzhou Central Hospital
    Zhengzhou, Henan, China
    Recruiting
08

References and documents

Publications

  • Bing HL, Wang Y, Li SY, Li YW, Wang QM, Li LM, Liu SQ, Hu ZH, Wang TW, Lu QW, Ran R, Wu Y, Xu SS, Li HJ, Huo J, Liu C, Hu AM, Xia ZY, Chu QJ. Reinforcement learning based automated anesthesia system for gastrointestinal endoscopy with a multicenter randomized trial. NPJ Digit Med. 2026 Apr 29;9(1):539. doi: 10.1038/s41746-026-02657-8. PubMed 42056274 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06857344
Lead sponsor
Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd.
Collaborators
Zhengzhou Central Hospital, Xinzheng Public People's Hospital, Henan Provincial People's Hospital, Anxi County Hospital, Jinjiang Municipal Hospital, Shanghai Sixth People's Hospital Fujian Campus
Responsible party
Sponsor
First posted
Mar 4, 2025
Start date
May 1, 2025
Primary completion
Sep 1, 2025 (estimated)
Completion
Oct 1, 2025 (estimated)
Last update
Aug 15, 2025

Study contacts

Dr. Chu
Contact
jimmynetchu@163.com
+86 138 3810 0696

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion